ERAS Program for Hepatic Resection Decreased Postoperative Complications
The effect of compliance with ERAS protocols on postoperative adverse events and length of hospital stay was evaluated in a single-center cohort study.
The effect of compliance with ERAS protocols on postoperative adverse events and length of hospital stay was evaluated in a single-center cohort study.
The combination of sintilimab and IBI305 improved progression-free survival in patients with unresectable hepatocellular carcinoma.
Overall survival was superior with donafenib.
Patient reported outcomes for quality of life, emotional and social functioning, and general disease symptoms were better with atezolizumab/bevacizumab compared with sorafenib monotherapy.
Investigators compared the cost-effectiveness of selective internal radiotherapy (SIRT) of that of sorafenib in the locally advanced hepatocellular carcinoma setting.
Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.
Combination tivozanib and durvalumab was found to be well-tolerated in patients with advanced, treatment-naïve hepatocellular carcinoma (HCC).
[Journal of Hepatocellular Carcinoma] Researchers at UT MD Anderson Cancer Center assessed the value of chest, abdominal, and pelvic CT in the surveillance of patients with HCC, and the potential drawbacks to the practice.
[Cancer Management and Research] Researchers present a simple classification method for assessing fatigue, which is proven to be a prognostic marker of TTP and OS in patients with HCC.
In the CRL, the FDA stated that the data from KEYNOTE-524/Study 116 did not demonstrate a meaningful advantage over available therapies for unresectable or metastatic HCC.